Randomization of Endovascular Treatment with Stent-retriever and/or Thromboaspiration versus Best Medical Therapy in Acute Ischemic Stroke due to Large Vessel Occlusion (RESILIENT-Extend)
Source: View publication →
The RESILIENT-Extend trial demonstrates that in a resource-limited setting, mechanical thrombectomy for large vessel occlusion stroke within the 8–24 hour time window, selected via non-contrast CT and CT angiography, significantly improves functional outcomes at 90 days compared to medical management alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study provides evidence that mechanical thrombectomy can be effectively implemented in resource-constrained environments to treat late-window stroke, potentially shifting global guidelines to expand access to care without requiring expensive advanced imaging.
Historical Context
The original RESILIENT trial established the efficacy of mechanical thrombectomy in Brazil's public health system within the 8-hour window. RESILIENT-Extend builds upon this by exploring the safety and efficacy of extending the treatment window to 24 hours using simplified, cost-effective diagnostic protocols, addressing a critical gap in stroke care equity for low- and middle-income countries.
Guided Discussion
High-yield insights from every perspective
What is the physiological basis for extending the mechanical thrombectomy window up to 24 hours in some patients, and why does this study suggest that advanced perfusion imaging might not be the only way to identify these patients?
Key Response
The core concept is the ischemic penumbra, which is salvaged by collateral circulation. While previous landmark trials (DAWN/DEFUSE-3) used CTP or MRI to prove the existence of salvageable tissue (mismatch), RESILIENT-Extend suggests that a high ASPECTS score on a simple Non-Contrast CT (NCCT) combined with CTA can serve as a proxy for good collaterals and a small core, even in the 8-24 hour window.
The DAWN and DEFUSE-3 trials established the 24-hour window for thrombectomy but required CTP or MRI for selection. How do the inclusion criteria of RESILIENT-Extend differ, and how does this impact the 'drip and ship' protocol in a community hospital setting?
Key Response
RESILIENT-Extend used NCCT (ASPECTS 6-10) and CTA for selection in the 8-24 hour window. This is practice-changing because many community hospitals lack 24/7 perfusion software or MRI access. If NCCT/CTA is sufficient to identify late-window candidates, the threshold for transferring patients to a comprehensive stroke center is lowered, potentially increasing the volume of eligible patients who were previously excluded by imaging constraints.
In RESILIENT-Extend, the treatment effect was robust despite the lack of perfusion-based selection. When considering 'slow progressors' versus 'fast progressors,' what are the risks of using NCCT-only selection in the 8-24 hour window compared to the volumetric 'core' assessment provided by RAPID or OLEA software?
Key Response
The primary risk is the 'visual-core mismatch.' NCCT is less sensitive than DWI or CTP for early ischemic changes (low ASPECTS). A 'fast progressor' might appear to have an ASPECTS of 7 on NCCT, but may already have an irreversibly infarcted core >70ml that is not yet hypodense. Fellows must weigh the benefit of expanded access against the risk of futile recanalization and increased intracranial hemorrhage (ICH) in patients with large, undetected cores.
RESILIENT-Extend was conducted in the Brazilian public health system (SUS). How should the resource-limited context of the trial influence our interpretation of the 'Best Medical Therapy' arm and the generalizability of the absolute risk reduction to high-resource environments?
Key Response
In resource-limited settings, the 'Best Medical Therapy' (BMT) may lack the intensity of stroke unit care found in high-resource centers. If the BMT arm performs worse than expected, the treatment effect (OR) of thrombectomy may be artificially inflated. However, the trial demonstrates that MT is a highly cost-effective intervention that can overcome systemic healthcare inequities, suggesting that expensive imaging is a barrier, not a requirement, for therapeutic efficacy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Discuss the methodological implications of using a 'simplified' imaging selection protocol in a randomized controlled trial. Does this design increase the 'pragmatic' nature of the trial at the expense of mechanistic purity, and how does this affect the statistical power required to show a shift in the mRS distribution?
Key Response
By using NCCT/CTA, the trial likely includes a more heterogeneous population than DAWN/DEFUSE-3 (which filtered for 'ideal' candidates). This increased variance usually requires a larger sample size to reach significance. However, if the treatment effect is large enough, a pragmatic design proves that the intervention is robust across real-world clinical variance, increasing the external validity and the likelihood of successful implementation in diverse healthcare systems.
A major concern with RESILIENT-Extend is the potential for 'selection bias by geography' and whether the adjudication of NCCT ASPECTS was centralized or performed by site investigators. Why would a tough reviewer flag the lack of core-volume quantification as a threat to the trial's internal validity?
Key Response
Reviewers would be concerned about inter-rater reliability of NCCT ASPECTS, which is notoriously variable. Without automated volumetric core assessment, the trial relies on the subjective interpretation of local investigators. If site investigators were unblinded (which they are in surgical trials), they might 'up-score' ASPECTS to include patients in the intervention arm, potentially confounding the results if not balanced by a blinded core laboratory adjudication.
Current AHA/ASA guidelines (Class 1, Level A) recommend CTP or MRI for MT selection in the 6-24 hour window based on DAWN/DEFUSE-3. Given the RESILIENT-Extend and MR CLEAN-LATE results, should the guidelines be updated to include NCCT/CTA-only selection as a Class 1 recommendation, or should it remain a lower 'alternative' level of evidence?
Key Response
The committee must decide if RESILIENT-Extend, combined with MR CLEAN-LATE, provides sufficient 'Level A' evidence to democratize late-window MT. Current guidelines (2019/2023 updates) are restrictive. Moving to NCCT/CTA-only selection would significantly expand the 'Standard of Care' globally. The committee must balance the high-quality evidence from RESILIENT-Extend against the potential for harm if NCCT is used by less experienced readers in non-study settings.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Endovascular treatment (intra-arterial treatment)
Population
Patients with acute ischemic stroke due to proximal arterial occlusion
Comparator
Usual care alone
Endpoint
Functional status at 90 days measured by modified Rankin Scale
DAWN Trial
Tested
Mechanical thrombectomy in the extended window
Population
Patients with acute ischemic stroke with a mismatch between clinical deficit and infarct volume 6-24 hours after last known well
Comparator
Standard medical therapy
Endpoint
Functional independence at 90 days
RESILIENT Trial
Tested
Mechanical thrombectomy plus best medical therapy
Population
Patients with acute ischemic stroke due to large vessel occlusion in Brazil
Comparator
Best medical therapy alone
Endpoint
Functional independence at 90 days (mRS 0-2)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis